REG - Aptamer Group PLC - AGM Statement

AptamerAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251127:nRSa1754Ja&default-theme=true

RNS Number : 1754J  Aptamer Group PLC  27 November 2025

 

27 November 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Annual General Meeting Statement

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, will
hold its Annual General Meeting (AGM) at 11:00 am today at the offices
of Aptamer Group, Windmill House, Innovation Way, York, YO10 5BR.

 

Dr Adam Hargreaves, Non-Executive Chairman, will provide the following
statement:

 

"Since becoming Chairman last year, I am delighted to report a period of
sustained commercial momentum and strategic progress. Lately, we have
announced a series of significant contract wins, including partnerships and
repeat business orders with three of the top 10 global pharmaceutical
companies. This has contributed to an order book of signed contracts for FY26
of £1.95 million with seven months of the year remaining. This provides the
Board with great confidence that revenue will materially exceed the prior
year's performance.

 

The consistent repeat business we have seen from top-tier pharmaceutical
companies signals both the strategic potential and the increasing value being
placed in our Optimer(®) platform by leading pharmaceutical companies. We
continue to focus on developing licensable assets and retaining intellectual
property or commercialisation rights in areas of high value, positioning the
Group to capture significant long-term value through licensing and royalties.
In our journey to reach a significant and critical value inflection point, it
is pleasing to see Aptamer cover increasing levels of its operating cost base.
 

 

Adding to our opportunity landscape, we launched a Biomarker Discovery Service
in August 2025, enhancing our capabilities to attract additional
fee-for-service revenues in high value areas. We have also advanced key
collaborations, including a therapeutic agreement with Invizius and a
water-borne pathogen detection project with Metir plc.

 

To support this growth, we successfully raised £1.8 million through a July
2025 placing, at a modest discount, providing capital for operational
expansion and Research and Development. Considering the solid progress, the
Group achieved an impressive uplift in share price and total market cap over
this past 12 months, positioning itself firmly as an established small-cap
life-sciences company listed on the AIM market. The Board firmly believes that
the growth trajectory has only just commenced and is encouraged by myriad
opportunities available within the field and our increasing repeat business
pipeline.

 

Looking ahead, we remain confident in our growing portfolio of licensable
assets and securing licensing deals with near-term royalties, which will allow
the Group to start building passive income streams. With ongoing investor
engagement through webinars and events, and a focus on intellectual property
retention, future licensing and success-based repeat business, we are
well-positioned to drive shareholder value.

 

The Board looks forward to updating shareholders on further progress in due
course."

The AGM will not provide any new material information. Results of the AGM will
be announced to the London Stock Exchange and placed on the Group's website,
in the usual way, as soon as practicable after the conclusion of the AGM.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott  
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 Andrew Thacker / Guy McDougall
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

Forward-Looking Statements

This announcement contains forward-looking statements. These relate to future
events or performance and include statements about expected revenues,
earnings, cash flows, business strategy and growth prospects. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from those expressed or implied due to factors including economic
conditions, competition, regulatory changes and industry trends. Past
performance is not a guide to future performance. No statement in this
announcement constitutes a profit forecast or profit estimate. The Company
undertakes no obligation to update these statements, except as required by law
or by any appropriate regulatory authority.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBFBLTMTMTBAA



            Copyright 2019 Regulatory News Service, all rights reserved